Based on this research, the combination of small-molecule inhibitors that disrupt the DPP9-KEAP1 complex with chemotherapy drugs could potentially improve the response of liver cancer patients to chemotherapy and prolong their survival. The gene discussed is DPP9; the disease is liver cancer.